FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093490614> ?p ?o ?g. }

• W2093490614 endingPage "350" @default.
• W2093490614 startingPage "347" @default.
• W2093490614 abstract "Purpose: To determine if the presence of perineural invasion (PNI) predicts biochemical recurrence in patients who underwent low-dose-rate brachytherapy for the treatment of localized prostate cancer. Methods and Materials: A retrospective case control matching study was performed. The records of 651 patients treated with brachytherapy between 1996 and 2003 were reviewed. Sixty-three of these patients developed biochemical failure. These sixty-three patients were then matched in a one-to-one ratio to patients without biochemical failure, controlling for biopsy Gleason score, clinical stage, initial prostate-specific antigen, age, and the use of androgen deprivation. The pathology of the entire cohort was then reviewed for evidence of perineural invasion on initial prostate biopsy specimens. The biochemical relapse free survival rates for these two groups were compared. Results: Cases and controls were well matched, and there were no significant differences between the two groups in age, Gleason grade, clinical stage, initial prostate-specific antigen, and the use of androgen deprivation. PNI was found in 19 (17%) patients. There was no significant difference in the rates of PNI between cases and controls, 19.6% and 14.3% respectively (p = 0.45). PNI did not correlate with biochemical relapse free survival (p = 0.40). Conclusion: Perineural invasion is not a significant predictor of biochemical recurrence in patients undergoing brachytherapy for prostate cancer. Purpose: To determine if the presence of perineural invasion (PNI) predicts biochemical recurrence in patients who underwent low-dose-rate brachytherapy for the treatment of localized prostate cancer. Methods and Materials: A retrospective case control matching study was performed. The records of 651 patients treated with brachytherapy between 1996 and 2003 were reviewed. Sixty-three of these patients developed biochemical failure. These sixty-three patients were then matched in a one-to-one ratio to patients without biochemical failure, controlling for biopsy Gleason score, clinical stage, initial prostate-specific antigen, age, and the use of androgen deprivation. The pathology of the entire cohort was then reviewed for evidence of perineural invasion on initial prostate biopsy specimens. The biochemical relapse free survival rates for these two groups were compared. Results: Cases and controls were well matched, and there were no significant differences between the two groups in age, Gleason grade, clinical stage, initial prostate-specific antigen, and the use of androgen deprivation. PNI was found in 19 (17%) patients. There was no significant difference in the rates of PNI between cases and controls, 19.6% and 14.3% respectively (p = 0.45). PNI did not correlate with biochemical relapse free survival (p = 0.40). Conclusion: Perineural invasion is not a significant predictor of biochemical recurrence in patients undergoing brachytherapy for prostate cancer." @default.
• W2093490614 created "2016-06-24" @default.
• W2093490614 creator A5001069772 @default.
• W2093490614 creator A5015241404 @default.
• W2093490614 creator A5062476184 @default.
• W2093490614 creator A5064373607 @default.
• W2093490614 creator A5091808340 @default.
• W2093490614 date "2006-06-01" @default.
• W2093490614 modified "2023-09-27" @default.
• W2093490614 title "Perineural invasion on prostate needle biopsy does not predict biochemical failure following brachytherapy for prostate cancer" @default.
• W2093490614 cites W174668522 @default.
• W2093490614 cites W1968484957 @default.
• W2093490614 cites W1975096840 @default.
• W2093490614 cites W1979292231 @default.
• W2093490614 cites W1988527037 @default.
• W2093490614 cites W1998012390 @default.
• W2093490614 cites W2012302620 @default.
• W2093490614 cites W2017249485 @default.
• W2093490614 cites W2028530629 @default.
• W2093490614 cites W2034898015 @default.
• W2093490614 cites W2050272614 @default.
• W2093490614 cites W2052427760 @default.
• W2093490614 cites W2063848716 @default.
• W2093490614 cites W2067743218 @default.
• W2093490614 cites W2083001307 @default.
• W2093490614 cites W2085178116 @default.
• W2093490614 cites W2116425797 @default.
• W2093490614 cites W2116944705 @default.
• W2093490614 cites W2120390866 @default.
• W2093490614 cites W2120983691 @default.
• W2093490614 cites W2126585743 @default.
• W2093490614 cites W2140804378 @default.
• W2093490614 cites W2143184739 @default.
• W2093490614 cites W2149871332 @default.
• W2093490614 cites W2152561234 @default.
• W2093490614 cites W2163820562 @default.
• W2093490614 cites W2402343233 @default.
• W2093490614 doi "https://doi.org/10.1016/j.ijrobp.2005.12.054" @default.
• W2093490614 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16545922" @default.
• W2093490614 hasPublicationYear "2006" @default.
• W2093490614 type Work @default.
• W2093490614 sameAs 2093490614 @default.
• W2093490614 citedByCount "16" @default.
• W2093490614 countsByYear W20934906142013 @default.
• W2093490614 countsByYear W20934906142014 @default.
• W2093490614 countsByYear W20934906142015 @default.
• W2093490614 countsByYear W20934906142017 @default.
• W2093490614 countsByYear W20934906142018 @default.
• W2093490614 countsByYear W20934906142020 @default.
• W2093490614 crossrefType "journal-article" @default.
• W2093490614 hasAuthorship W2093490614A5001069772 @default.
• W2093490614 hasAuthorship W2093490614A5015241404 @default.
• W2093490614 hasAuthorship W2093490614A5062476184 @default.
• W2093490614 hasAuthorship W2093490614A5064373607 @default.
• W2093490614 hasAuthorship W2093490614A5091808340 @default.
• W2093490614 hasConcept C121608353 @default.
• W2093490614 hasConcept C126322002 @default.
• W2093490614 hasConcept C126894567 @default.
• W2093490614 hasConcept C143998085 @default.
• W2093490614 hasConcept C146357865 @default.
• W2093490614 hasConcept C151730666 @default.
• W2093490614 hasConcept C167135981 @default.
• W2093490614 hasConcept C2775934546 @default.
• W2093490614 hasConcept C2776235491 @default.
• W2093490614 hasConcept C2777008409 @default.
• W2093490614 hasConcept C2777154038 @default.
• W2093490614 hasConcept C2777416452 @default.
• W2093490614 hasConcept C2777899217 @default.
• W2093490614 hasConcept C2779466945 @default.
• W2093490614 hasConcept C2780192828 @default.
• W2093490614 hasConcept C2781406297 @default.
• W2093490614 hasConcept C509974204 @default.
• W2093490614 hasConcept C71924100 @default.
• W2093490614 hasConcept C86803240 @default.
• W2093490614 hasConceptScore W2093490614C121608353 @default.
• W2093490614 hasConceptScore W2093490614C126322002 @default.
• W2093490614 hasConceptScore W2093490614C126894567 @default.
• W2093490614 hasConceptScore W2093490614C143998085 @default.
• W2093490614 hasConceptScore W2093490614C146357865 @default.
• W2093490614 hasConceptScore W2093490614C151730666 @default.
• W2093490614 hasConceptScore W2093490614C167135981 @default.
• W2093490614 hasConceptScore W2093490614C2775934546 @default.
• W2093490614 hasConceptScore W2093490614C2776235491 @default.
• W2093490614 hasConceptScore W2093490614C2777008409 @default.
• W2093490614 hasConceptScore W2093490614C2777154038 @default.
• W2093490614 hasConceptScore W2093490614C2777416452 @default.
• W2093490614 hasConceptScore W2093490614C2777899217 @default.
• W2093490614 hasConceptScore W2093490614C2779466945 @default.
• W2093490614 hasConceptScore W2093490614C2780192828 @default.
• W2093490614 hasConceptScore W2093490614C2781406297 @default.
• W2093490614 hasConceptScore W2093490614C509974204 @default.
• W2093490614 hasConceptScore W2093490614C71924100 @default.
• W2093490614 hasConceptScore W2093490614C86803240 @default.
• W2093490614 hasIssue "2" @default.
• W2093490614 hasLocation W20934906141 @default.
• W2093490614 hasLocation W20934906142 @default.
• W2093490614 hasOpenAccess W2093490614 @default.
• W2093490614 hasPrimaryLocation W20934906141 @default.

• next